SBIR-STTR Award

Treatment Of Wound Infection With Novel Uncharged Silver Carbene Complexes
Profile last edited on: 9/20/2013

Program
SBIR
Agency
NIH | NIAID
Total Award Amount
$298,369
Award Phase
1
Principal Investigator
David J Vachon
Activity Indicator

Company Information

Iasis Molecular Sciences LLC

3305 East Moran Vista Lane
Spokane, WA 99223
   (509) 844-2734
   djvachon@iasismolecular.com
   www.iasismolecular.com
Multiple Locations:   
Congressional District:   05
County:   Spokane

Phase I

Phase I year
2012
Phase I Amount
$298,369
Three novel uncharged silver carbene microbicides that have been shown to be effective against a wide variety of pathogens will be formulated into two different ointment formulations and tested in an infected healing model in the diabetic rat. Formulation of the silver carbenes into one of either a transparent (gel) wound ointment that will allow viewing of the wound while being treated or an occlusive petrolatum-based ointment that is anticipated to have different moisture retention and drug delivery characteristics that a water-based gel will be carried out. The major specific aims of the proposed research involve the preparation & formulation/processing of the silver carbene antimicrobial agents into an ointment form, chemical and biological characterization, determination of maximum tolerated doses, and evaluation in an infected wound model in the rat. The biological characterization involves the determination of the MIC90 for each compound and evaluation of the toxicity of each compound formulated into an ointment over a two log range starting at a concentration (in the ointment) at the MIC90. The primary objectives of the proposed therapy are: 1) resolution of infection, 2) minimization of inflammation, and 3) encouragement of wound resolution. This innovative and rational approach to a topical antimicrobial therapy is founded on the basis of several different studies that have revealed promising bio-applicable attributes of these silver carbene complexes. The end-goal of this project is to enable the next phase of development of one or more of these novel microbicidal compounds that will be targeted for the treatment of infected chronic wounds and burns while developing a greater understanding of the mechanisms by which these compounds work.

Public Health Relevance:
Diabetic foot ulcers are a common type of chronic wound affecting as many as 25% of all diabetics and in many cases diabetics develop infection as a consequence of an impaired inflammatory response. Infection can greatly complicate treatment and outcomes for diabetic foot ulcers with 65% of all patients developing osteomyelitis and amputation in 14-24% of the osteomyelitis group (American Diabetes Association, 1999). Complications associated with foot ulcers account for 20-25% of all hospitalizations costing billions of dollars annually and despite the important medical advances that have been made in the treatment of diabetic foot ulcers in the past fifty years, there remains a significant need for more effective therapies to combat infection and impaired wound healing in this patient population.

Public Health Relevance Statement:
Diabetic foot ulcers are a common type of chronic wound affecting as many as 25% of all diabetics and in many cases diabetics develop infection as a consequence of an impaired inflammatory response. Infection can greatly complicate treatment and outcomes for diabetic foot ulcers with 65% of all patients developing osteomyelitis and amputation in 14-24% of the osteomyelitis group (American Diabetes Association, 1999). Complications associated with foot ulcers account for 20-25% of all hospitalizations costing billions of dollars annually and despite the important medical advances that have been made in the treatment of diabetic foot ulcers in the past fifty years, there remains a significant need for more effective therapies to combat infection and impaired wound healing in this patient population.

NIH Spending Category:
Bioengineering; Biotechnology; Clinical Research; Diabetes; Emerging Infectious Diseases; Infectious Diseases

Project Terms:
Accounting; Address; Affect; American; Amputation; Animal Model; Animals; Antibiotics; antimicrobial; antimicrobial drug; Back; Bacteria; base; Biological; biomaterial compatibility; Burn injury; carbene; Characteristics; Chemicals; Chronic; combat; Complex; cost; cytotoxicity; Dermal; design; Development; Diabetes Mellitus; diabetic; Diabetic Foot Ulcer; diabetic rat; Dose; Drug Delivery Systems; Drug Formulations; effective therapy; Effectiveness; Erythema; Evaluation; Fibroblasts; Foot Ulcer; Gel; Goals; Healed; healing; Histocompatibility; Hospitalization; Hydrogels; Imagery; Impaired wound healing; improved; In Vitro; in vivo; indexing; Infection; Inflammation; Inflammatory Response; innovation; Invaded; Liquid substance; Maintenance; Maximum Tolerated Dose; Measurement; Measures; Medical; Methicillin Resistance; microbial; Microbial Biofilms; microbicide; Modeling; Nature; novel; Ointments; Osteomyelitis; Outcome; Oxidative Stress; pathogen; patient population; Patients; Perfusion; Peroxidases; Petrolatum; Phase; Preparation; Process; programs; Pseudomonas aeruginosa; Rattus; Research; Resistance; resistant strain; Resolution; Silver; Site; Solubility; Staging; Staphylococcus aureus; Sterile coverings; Streptozocin; Sulfadiazine; Symptoms; Technology; Testing; Therapeutic; Therapeutic Agents; Thick; Tissues; Topical Antibiotic; Toxic effect; Treatment outcome; Water; Work; wound; Wound Infection

Phase II

Phase II year
---
Phase II Amount
---